Skip to content

GRI Bio, Inc.

GRI

CIK 0001824293 · Pharmaceutical Preparations · Nasdaq

  • Vallon Pharmaceuticals, Inc. (until 2023-04-21)
← back to feed
Revenue (TTM)
$0
−100.0% YoY Q1 May 2026
Net Income (TTM)
−$11.3M
−45.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$166.50
+92.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$8.21M
Q1 May 2026
Cash
$11.05M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
1.77M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings